Indegene Q1 FY27 Results Analysis: Revenue Surges 40%, PAT Flat on Elevated Costs (INDGN)

CompoundingAI Research Updated July 31, 2026 2 min read
Positive

Indegene Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 1,063.10 Cr (+39.73% YoY) and PAT growth of -0.17% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 30, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 1,063.10 Cr (+39.73% YoY)
PAT (Q1)Rs. 116.20 Cr (-0.17% YoY)
EBITDA margin16.39% (-402 bps YoY)
EPS (Q1)Rs. 4.84 (-0.41% YoY)
Market capRs. 12,399.75 Cr
CMPRs. 514.70

Quarter Snapshot

Indegene delivered strong revenue growth of 39.73% YoY, driven by acquisitions and organic momentum. EBITDA margin saw its first sequential improvement in a year, rising 211 bps QoQ to 16.39%, in line with management's guidance. However, PAT was flat due to elevated D&A and acquisition costs, and the margin remains 402 bps below last year. Management's trajectory towards a ~20% margin in H2 FY27 is on track, supported by declining D&A from Q2. The key risk remains the pending tax dispute of over Rs.167 Cr.

Key Investment Insights

Key Positives

  • Revenue grew 39.73% YoY to Rs.1,063.1 Cr.
  • EBITDA margin improved 211 bps QoQ to 16.39%, first sequential uptick.
  • EBITDA grew 21.56% QoQ to Rs.174.2 Cr.
  • Enterprise Commercial Solutions segment grew 43.96% YoY.
  • Standalone revenue grew 33.29% YoY with EBITDA margin expansion of 331 bps YoY to 17.67%.
  • TCPA exceptional provision unchanged at Rs.20.3 Cr, no additional provision in Q1.

Risk Factors

  • PAT flat YoY (−0.17%) despite 39.73% revenue growth.
  • EBITDA margin 402 bps below Q1 FY26 level of 20.41%.
  • Other expenses surged 85.32% YoY due to acquisition cost base.
  • D&A more than doubled YoY (+104.17%) suppressing PAT.
  • Income tax dispute of Rs.43.69 Cr + Rs.123.41 Cr disclosed.
  • Standalone revenue declined 7.47% QoQ, indicating sequential growth driven by subsidiaries.
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now